LifeMD Announces Strategic Shift Toward Direct GLP-1 Fulfillment and Enterprise Partnerships
During its third quarter 2026 earnings call, LifeMD (LFMD) announced a significant strategic pivot toward direct pharmacy distribution of branded GLP-1 weight-loss medications. By securing direct fulfillment agreements with Eli Lilly and Novo Nordisk, the company aims to integrate prescribing and dispensing into a single telehealth platform, thereby increasing gross profit margins per subscriber. The company is also leveraging an enterprise partnership with AT&T to access 100 million customers at a significantly lower acquisition cost compared to traditional digital marketing. Additionally, LifeMD has successfully transitioned its patient base toward long-term commitment; by lowering introductory pricing, the share of new patients opting for multi-month weight management plans rose from 25% to 85%, while customer acquisition costs fell by 40%.

Topics: Corporate partnerships GLP-1 weight management Pharmacy fulfillment Telehealth